Articles tagged with Glioblastomas
Researchers developed a nanotechnology method to deliver medication through the blood-brain barrier, overcoming its selectivity and expanding therapeutic options for glioblastoma treatment. The technique demonstrated improved tumor shrinkage and survival rates in mice, paving the way for further preclinical studies.
Researchers have developed a novel zebrafish xenograft platform to screen for novel treatments for glioblastoma, an aggressive brain tumor. The platform uses zebrafish avatars to model glioblastoma cells from individual patients, allowing researchers to identify patient-specific targets and potential treatments.
The INSIGhT trial has reported initial results, with patients on abemaciclib and neratinib experiencing longer progression-free survival than those receiving standard therapy. The adaptive platform trial uses Bayesian Adaptive Randomization to identify therapies that benefit patients more efficiently.
Researchers at The Hospital for Sick Children have discovered a designer peptide that targets a previously unknown protein-protein interaction in glioblastoma cells, resulting in the death of tumor cells across all subtypes. The treatment approach showed robust therapeutic efficacy and no side effects in preclinical models.
Researchers at UTSA are studying the bioactive properties of Sweet Annie, a plant used in traditional Chinese medicine for over 2,000 years. The study reveals that arteannuin B from the plant has anti-COVID and anti-glioblastoma properties, offering new avenues for targeted therapy.
Researchers at UCLA Jonsson Comprehensive Cancer Center aim to overcome brain tumor's limited treatment options with ERAS-801, a brain-penetrant inhibitor showing promise in preclinical models. The team is testing the treatment in early clinical trials for patients diagnosed with glioblastoma.
Researchers found that tumors with metastasis to the brain respond better to immunotherapy due to effective priming outside the brain. Glioblastoma, an aggressive brain cancer, does not respond well due to impaired priming step.
Researchers at Kanazawa University found a link between nuclear pore complex alterations and glioblastoma. They demonstrated that NUP107 proteins overexpression degrades the function of p53, a crucial cancer-preventing protein. Further studies are needed to uncover the molecular pathways at play.
Researchers find immunotherapy treatment anti-CTLA-4 leads to greater survival in mice with glioblastoma and discover new way cells kill cancer by triggering microglia, specialized immune cells in the brain. This breakthrough could lead to more effective treatments for human brain cancer.
Researchers have identified a new therapeutic target for glioblastoma brain cancer by finding that the 'don't eat me!' signal sent by cancer cells can be blocked using antibodies. This breakthrough suggests that existing immunotherapies may be effective against glioblastomas if the receivers on macrophages are switched off.
Researchers at Tokyo Institute of Technology developed a novel boron agent that selectively accumulates in brain tumor cells, exhibits enhanced blood retention, and can be administered at low doses. The agent, PBC-IP, shows promising results in preclinical studies, highlighting its potential for radiotherapy in treating glioblastoma.
Researchers at Nanyang Technological University discover ponatinib, an existing cancer drug, can block key steps in alternative lengthening of telomeres (ALT) mechanism. This could lead to new treatment options for ALT cancers, which currently lack targeted therapies.
A study published in Nature reveals that neurons in remote brain regions promote the expression of genes from glioblastoma tumors, leading to tumor infiltration. The researchers found that callosal projection neurons play a key role in this process, and that SEMA4F is an essential factor for glioma progression.
Researchers found that combining radiation with a genetically engineered oncolytic vaccinia virus improved treatment outcomes for glioblastoma brain tumors in mice. The combination showed a 15% cure rate and 62% rejection of new cancer cells, outperforming radiation alone.
Researchers have identified a potential breakthrough in glioblastoma treatment, combining a novel viral therapy with a checkpoint inhibitor to attack tumor cells. In phase 2 trials, around 10% of patients showed significant tumor shrinkage and improved overall survival, offering hope for better treatment options.
A recent study led by UCLA researchers has identified a potential new strategy for treating glioblastoma by targeting a specific metabolic process in cancer cells. The study found that disrupting this process could make glioblastoma cells more vulnerable to cell death, offering hope for new treatment options.
Penn Medicine researchers will present results from clinical trials for recurrent glioblastoma and metastatic breast cancer. Experts will also present studies on serious illness conversations, Medicaid expansion impact, and infertility among female oncologists.
Researchers at the University of Gothenburg have developed a method to kill glioblastoma brain tumours by blocking stress in cancer cells. The treatment, which involves inserting a specially developed molecule into cells, shows promising results with no side effects.
A clinical trial combining TVB-2640 and bevacizumab showed a six-month progression-free survival improvement in patients with recurrent high-grade glioblastoma, warranting further study. The treatment's side effects were mild, but the overall survival of participants was not statistically significant compared to historic controls.
Researchers discovered that FDA-approved HDAC-inhibitors can impact energy metabolism in solid tumor cells, including glioblastoma. The combination of HDAC-inhibitors and imipridones may synergize to enhance killing of GBM cells by reversing cellular respiration.
A Phase I/II clinical trial combining intratumoral delivery of an engineered oncolytic virus with subsequent immunotherapy improved survival outcomes in a subset of patients with recurrent glioblastoma. The study demonstrated the combination was well-tolerated, with no dose-limiting toxicities.
Researchers developed a novel combination therapy that eradicates tumors in select patients, with prolonged survival rates. The therapy has shown promise in treating glioblastoma, a notoriously difficult-to-treat primary brain cancer.
Brain cancer cells use mitochondria from healthy astrocytes to boost energy production and amplify cancer stem cells, making glioblastoma more deadly and difficult to treat. Researchers discovered that acquiring mitochondria is a common process in glioblastoma, with implications for developing new treatments.
Glioblastoma steals cognitive faculties as it spreads, but its insidious ability to infiltrate neighboring networks may be its undoing. Researchers found neural activity can restructure connections in surrounding tissue, causing decline. The drug gabapentin blocks this growth-causing activity in mice with glioblastoma.
A multi-institutional phase 3 clinical trial found that a cancer stem cell test can accurately decide more effective treatments and lead to increased survival for patients with recurrent glioblastoma. ChemoID, a CLIA-accredited diagnostic test, was used to select chemotherapy treatments, resulting in significantly lower risk of death a...
Researchers identified three novel dual-purpose therapeutic targets using PandaOmics, which could treat both aging and glioblastoma multiforme. The target hypotheses include cyclic nucleotide gated channel subunit alpha 3 (CNGA3), glutamate dehydrogenase 1 (GLUD1) and sirtuin 1 (SIRT1).
Three high school students co-authored a paper using AI engine PandaOmics to discover new therapeutic targets for glioblastoma multiforme, a common and aggressive malignant brain tumor. The study identified three genes strongly correlated with both aging and glioblastoma as potential therapeutic targets.
Scientists successfully opened the blood-brain barrier using a novel ultrasound device, delivering chemotherapy to treat glioblastoma patients. The treatment increased drug concentrations by 4-6 times and was safe and well-tolerated.
A novel gel has cured 100% of mice with aggressive brain cancer, a breakthrough that could lead to new treatments for glioblastoma. The gel combines an anticancer drug and antibody to target tumor cells and stimulate the immune system.
A team of researchers has discovered that a naturally produced chemical in the body helps glioblastoma cells go unrecognized by the immune system. The findings could lead to the development of new and more effective treatments for this aggressive brain cancer.
Researchers develop mechanical nanosurgery to destroy tumour cells from within, reducing GBM tumour size universally, including in TMZ-resistant cases. The treatment uses magnetically controlled carbon nanotubes to provide mechanical stimulation, damaging cellular structures and causing tumour cell death.
Dominique Higgins and his team found that a specialized diet can induce ferroptosis, a type of cell death, in glioblastoma cells, making chemotherapy drugs more effective. This approach has shown promise in animal models and is being explored as a potential treatment for brain tumors.
Researchers discovered that tumors with specific genetic mutations may evade the immune system, and a new class of immunotherapies targets these cells. The study's findings suggest that genetic testing could identify patients more likely to benefit from these therapies.
Two compounds, A5 and C1, have shown promising results in inhibiting the growth of glioblastoma cells, a type of aggressive brain cancer. Further research is needed to confirm their effectiveness on normal nerve cells and to move towards clinical trials.
Researchers at Penn State College of Medicine identified a biomarker, IL13Rα2, in blood plasma to diagnose and track glioblastoma. Elevated levels of IL13Rα2 predicted longer overall survival, suggesting tissue healing.
Researchers identify the minimum contribution of TACC3 for FGFR3-TACC3 fusion protein activation, revealing a novel target for treating FGFR translocation-driven cancers. The study shows that clinically identified FGFR3-TACC3 fusion proteins differ in biological activity depending on specific breakpoints.
Glioblastoma patients have a median survival time of 15 months due to the rapid infiltration of brain tissue. Cellular senescence, previously thought to be only a marker of aging, is now linked to cancer progression, with senescent cells promoting tumor growth and immune evasion.
Researchers have developed a sophisticated AI algorithm, SPHINKS, that can refine omics datasets and pinpoint protein kinases responsible for tumor growth in glioblastoma. The algorithm has the potential to provide personalized treatments for patients with aggressive brain cancer.
Researchers at Massachusetts General Hospital found that losartan can reduce the expression of inflammatory enzymes responsible for immunotherapy-related edema. The study suggests that losartan may allow patients to continue receiving immune checkpoint inhibitors without developing adverse effects in the brain.
Researchers from UTSA and UT Health San Antonio are developing compounds that target the estrogen receptor-beta, which suppresses cancer growth. The goal is to identify a novel ER-beta agonist with potential as a therapeutic strategy for treating GBM in patients.
Researchers are launching a clinical trial testing azeliragon, a RAGE inhibitor, with chemoradiotherapy to re-sensitize brain tumours that resist radiotherapy. The trial aims to predict radioresistance in brain metastasis using liquid biopsy.
A team of researchers from Korea and USA identified the importance of lipid homeostasis in overcoming brain cancer radioresistance. They found that regulating diacylglycerol kinase B and diacylglycerol acyltransferase 1 could potentially sensitize brain cancer cells to radiotherapy, offering a new treatment strategy.
A new study led by Massachusetts General Hospital researchers reveals that an investigational drug called YTX-7739 can delay the growth of brain tumors and increase their sensitivity to conventional chemotherapy. The drug works by inhibiting de novo lipid synthesis, a process used by cancer cells for energy production.
A team of researchers from Cold Spring Harbor Laboratory has made a breakthrough in understanding the deadly brain cancer glioblastoma. By linking the BRD8 protein to another key protein, P53, they have identified a potential target for new treatments that could extend patient survival and improve outcomes.
UCSF researchers identified glioma's cellular source of recurrent disease, finding cells shift to mesenchymal, radiation-resistant phenotype in response to standard therapy. Paracrine signals from tumor microenvironment drive this transition through AP1 pathway, leading to therapy resistance and tumor recurrence.
Researchers have identified three new subtypes of glioblastoma, a type of brain cancer, based on the presence of specific non-cancer cells. These subtypes may help identify targeted therapies, such as immunotherapies, for improved patient outcomes.
Researchers at UCLA Health have made significant breakthroughs in understanding deadly brain cancer and the role of housing interventions. A study found a cancer vaccine to be highly effective in treating glioblastoma multiforme, a nearly lethal brain cancer. Additionally, a survey highlighted the need for increased diversity in gastro...
A study published in Trends in Cancer suggests that targeting vulnerabilities in glioblastoma cancer cells, which maintain resemblance to the cells of origin, may lead to effective therapies. The research aims to identify ways to block these identity shifts and develop personalized treatments.
Kevin McHugh, a Rice bioengineer, has received the Distinguished Scientist Award from The Sontag Foundation for his work on gene editing to defeat glioblastoma multiforme. His approach involves delivering gene therapy agents directly to tumor cells, aiming to improve survival and reduce side effects.
Researchers demonstrate a new way to deliver medication to malignant brain tumors in mice, using a modified peptide that can penetrate the blood-brain barrier. The study shows promising results, with a 50% increase in survival rate for treated mice, and offers hope for future treatment breakthroughs.
A new study successfully tested an implantable pump that delivers chemotherapy directly to the brain, bypassing the blood-brain barrier. The treatment effectively kills brain tumor cells and offers a safe way to treat patients with brain cancer.
Researchers found that reducing SAMHD1 levels made brain tumor cells sensitive to chemotherapy drugs and slowed cell growth. They also suspect that glioblastoma alters SAMHD1's function to aid its own survival and treatment resistance.
A critical new pathway to treating glioblastoma, a deadly brain tumor, may be found in the complex diversity of tumor tissue. CDI scientists identified lipids with potential therapeutic value, highlighting the importance of targeting signaling pathways in relation to cell function and resistance to therapy.
The study found that BRAF alterations, particularly Class I mutations like v600E, are associated with improved overall survival in adults with glioma. However, the effectiveness of targeted therapies depends on the specific type and combination of genetic alterations driving the cancer.
Researchers at UCLA Jonsson Comprehensive Cancer Center and Semel Institute identified the gene P300 as a potential therapeutic target for treatment-resistant brain cancer glioblastoma multiforme. By blocking P300, tumor cells can be prevented from recovering and growing under the hostile conditions created by radiation therapy.
WayPath Pharma has been awarded a $225,000 Phase I Small Business Technology Transfer (STTR) award to develop new metabolic drugs targeting tumor stem cells and crossing the blood-brain barrier. The funding aims to advance treatment options for glioblastoma, a highly aggressive brain cancer with limited treatment options.
A new study has uncovered a previously unknown genetic process that could inform the development of novel treatment options for glioblastoma (GBM), a virtually incurable brain tumor. The epidermal growth factor receptor (EGFR) signaling pathway and long non-coding RNA molecules, such as lncEPAT, play critical roles in GBM tumorigenesis.
Researchers have identified a small molecule drug, SHP656, that can target the circadian clock proteins responsible for glioblastoma's recurrence and spread. The drug has shown promise in reducing cancer stem cell growth without harming normal stem cells.
A potential new treatment for glioblastomas, a deadly form of brain tumor, is being researched using the medication letrozole. Studies have shown that letrozole can be effective in killing tumor cells and reaching target tissue safely.
Monon Bioventures has received a grant to develop a novel glioblastoma treatment using armed natural killer cells. The treatment, created by Purdue University researcher Sandro Matosevic, shows promise in preclinical proof of concept and aims to manufacture the therapeutic for clinical studies.